Our website use cookies to improve and personalize your experience and to display advertisements (if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies.

More African countries set to approve malaria shot; 20 million doses ready in 2023

More African countries set to approve malaria shot; 20 million doses ready in 2023

JENNIFER RIGBY AFRICAN countries are lining up to approve a new vaccine for malaria, with 20 million doses available for them to buy this year, the shot’s manufacturer told Reuters. This week, Nigeria's medicines regulator followed Ghana's, with the two nations becoming the first countries in the world to back the new R21 vaccine, developed by scientists at Oxford University and manufactured by the Serum Institute of India and Novavax. The move was unusual as it came before the World Health Organization's approval. African countries that do not have extensive resources for drug regulation have previously relied on the U.N. agency to initially review…
Read More
Novavax sees start of U.S. COVID-19 vaccine trial in coming weeks after second delay

Novavax sees start of U.S. COVID-19 vaccine trial in coming weeks after second delay

VACCINE maker Novavax Inc has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November, the company has announced. It is the second time that Novavax, which already has a late-stage UK trial underway, has rescheduled the Phase 3 trial after first flagging an October start, hampered by issues in scaling up its manufacturing. Shares of the U.S.-based company, which lags behind larger rivals Pfizer Inc and Moderna Inc in their COVID-19 vaccine development timelines, fell 6% on the latest delay. Novavax plans…
Read More
Novavax to produce 150 million vaccine doses per month

Novavax to produce 150 million vaccine doses per month

LUDWIG BURGER NOVAVAX expects to produce up to 150 million COVID-19 vaccine doses monthly by May or June, its chief executive told Reuters, after reporting interim data that showed its shot to be 89% effective in a UK trial. Novavax expects to complete the clinical trial for its experimental COVID-19 vaccine in the next few weeks, but is already working on manufacturing to be able to reach full production capacity quickly, Chief Executive Officer Stanley Erck said. "We should be at full capacity starting in May or June, maybe as much as one hundred and fifty million doses per month…
Read More